Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | WHR1 | P49842 | 1/20 | 0.71 |
| ▸ | KMT5A | Q9NQR1 | 13/20 | 0.66 |
| ▸ | DNMT3A | Q9Y6K1 | 2/20 | 0.59 |
| ▸ | EHMT2 | Q96KQ7 | 3/20 | 0.53 |
| ▸ | KDM1A | O60341 | 2/20 | 0.53 |
| ▸ | RCOR1 | Q9UKL0 | 2/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29385210 | 1.00 | WHR1 (0.71) | WHR1KMT5ADNMT3AEHMT2KDM1A | |
| SCHEMBL5049818 | 0.88 | WHR1 (0.76) | WHR1KMT5AEHMT2 | |
| SCHEMBL22144630 | 0.83 | WHR1 (1.00) | WHR1KMT5AEHMT2 | |
| SCHEMBL25361551 | 0.80 | KMT5A (0.71) | WHR1KMT5A | |
| SCHEMBL25360225 | 0.79 | KMT5A (0.70) | WHR1KMT5A | |
| SCHEMBL30197751 | 0.79 | EHMT2 (0.64) | KMT5ADNMT3AEHMT2KDM1ARCOR1 | |
| SCHEMBL18103392 | 0.79 | EHMT2 (0.64) | KMT5ADNMT3AEHMT2KDM1ARCOR1 | |
| SCHEMBL25361990 | 0.77 | KMT5A (0.62) | WHR1KMT5AEHMT2 | |
| SCHEMBL18095981 | 0.77 | DNMT3A (0.59) | WHR1KMT5ADNMT3AEHMT2KDM1A | |
| SCHEMBL14095306 | 0.76 | ADRA1A (0.68) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170354655-A1 | TLR INHIBITOR AND BRUTON'S TYROSINE KINASE INHIBITOR COMBINATIONS | PHARMACYCLICS LLC | 2017-12-14 | — | — | US | claimed |
| EP-3220912-A1 | TLR INHIBITOR AND BRUTON'S TYROSINE KINASE INHIBITOR COMBINATIONS | Pharmacyclics LLC (US) | 2017-09-27 | — | — | EP | claimed |
| WO-2016081460-A1 | TLR INHIBITOR AND BRUTON'S TYROSINE KINASE INHIBITOR COMBINATIONS | PHARMACYCLICS LLC (US) | 2016-05-26 | — | — | WO | claimed |
| US-20220296628-A1 | RNA COMBINATIONS AND COMPOSITIONS WITH DECREASED IMMUNOSTIMULATORY PROPERTIES | CUREVAC AG (DE) | 2022-09-22 | — | — | US | disclosed |
| EP-4013880-A1 | RNA COMBINATIONS AND COMPOSITIONS WITH DECREASED IMMUNOSTIMULATORY PROPERTIES | CureVac AG (DE) | 2022-06-22 | — | — | EP | disclosed |
| WO-2021028439-A1 | RNA COMBINATIONS AND COMPOSITIONS WITH DECREASED IMMUNOSTIMULATORY PROPERTIES | CUREVAC AG (DE) | 2021-02-18 | — | — | WO | disclosed |
| US-20170354655-A1 | TLR INHIBITOR AND BRUTON'S TYROSINE KINASE INHIBITOR COMBINATIONS | PHARMACYCLICS LLC | 2017-12-14 | — | — | US | disclosed |
| EP-3220912-A1 | TLR INHIBITOR AND BRUTON'S TYROSINE KINASE INHIBITOR COMBINATIONS | Pharmacyclics LLC (US) | 2017-09-27 | — | — | EP | disclosed |
| WO-2016081460-A1 | TLR INHIBITOR AND BRUTON'S TYROSINE KINASE INHIBITOR COMBINATIONS | PHARMACYCLICS LLC (US) | 2016-05-26 | — | — | WO | disclosed |
| US-7410975-B2 | Small molecule toll-like receptor (TLR) antagonists | COLEY PHARMACEUTICAL GROUP, INC. (US) | 2008-08-12 | — | — | US | disclosed |
| US-7410975-B2 | Small molecule toll-like receptor (TLR) antagonists | COLEY PHARMACEUTICAL GROUP, INC. (US) | 2008-08-12 | — | — | US | disclosed |
| US-7410975-B2 | Small molecule toll-like receptor (TLR) antagonists | COLEY PHARMACEUTICAL GROUP, INC. (US) | 2008-08-12 | — | — | US | disclosed |
| US-20070232622-A1 | Small molecule toll-like receptor (TLR) antagonists | COLEY PHARMACEUTICAL GMBH (DE) | 2007-10-04 | — | — | US | disclosed |
| US-20070232622-A1 | Small molecule toll-like receptor (TLR) antagonists | COLEY PHARMACEUTICAL GMBH (DE) | 2007-10-04 | — | — | US | disclosed |
| US-20070232622-A1 | Small molecule toll-like receptor (TLR) antagonists | COLEY PHARMACEUTICAL GMBH (DE) | 2007-10-04 | — | — | US | disclosed |
| US-20050119273-A1 | Small molecule toll-like receptor (TLR) antagonists | COLEY PHARMACEUTICAL GMBH (DE) | 2005-06-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050119273-A1 | Small molecule toll-like receptor (TLR) antagonists | TLR3, TLR8, TLR7 | WHR1 3876/4885KMT5A 698/4885DNMT3A 915/4885 |
| US-20070232622-A1 | Small molecule toll-like receptor (TLR) antagonists | TLR3, TLR8, TLR7 | WHR1 3876/4885KMT5A 698/4885DNMT3A 915/4885 |
| US-20170354655-A1 | TLR INHIBITOR AND BRUTON'S TYROSINE KINASE INHIBITOR COMBINATIONS | BTK, TLR3, TLR9 | WHR1 2359/4885KMT5A 1586/4885DNMT3A 1040/4885 |
| US-20220296628-A1 | RNA COMBINATIONS AND COMPOSITIONS WITH DECREASED IMMUNOSTIMULATORY PROPERTIES | TLR3, EIF2AK2, STING1 | WHR1 1687/4885KMT5A 3765/4885DNMT3A 1762/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.